CN104926808B - 二氢嘧啶类化合物及其在药物中的应用 - Google Patents
二氢嘧啶类化合物及其在药物中的应用 Download PDFInfo
- Publication number
- CN104926808B CN104926808B CN201510324031.7A CN201510324031A CN104926808B CN 104926808 B CN104926808 B CN 104926808B CN 201510324031 A CN201510324031 A CN 201510324031A CN 104926808 B CN104926808 B CN 104926808B
- Authority
- CN
- China
- Prior art keywords
- methyl
- esi
- independently
- dihydropyrimidine
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)=NN(C)C=C Chemical compound CC(*)=NN(C)C=C 0.000 description 28
- QMRRMNTVPHRRON-JICONFDSSA-N C/C(/CN)=C(/N=C\C=C)\F Chemical compound C/C(/CN)=C(/N=C\C=C)\F QMRRMNTVPHRRON-JICONFDSSA-N 0.000 description 1
- AFOPCURQYRRFRQ-UHFFFAOYSA-N CC(C)c1ccc[o]1 Chemical compound CC(C)c1ccc[o]1 AFOPCURQYRRFRQ-UHFFFAOYSA-N 0.000 description 1
- WITWHKSPECQWBT-RBFZIWAESA-N CCC(OC[C@@H]1OCCN(CC(NC(c2n[nH]cn2)=NC2c(c(Br)c3)ccc3F)=C2C(OCC)=O)C1)=O Chemical compound CCC(OC[C@@H]1OCCN(CC(NC(c2n[nH]cn2)=NC2c(c(Br)c3)ccc3F)=C2C(OCC)=O)C1)=O WITWHKSPECQWBT-RBFZIWAESA-N 0.000 description 1
- KXEOSXSMPDLYKW-KKFHFHRHSA-N CCOC(C1=C(CN(CCOC2)[C@@H]2C(NOC)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)[C@@H]2C(NOC)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O KXEOSXSMPDLYKW-KKFHFHRHSA-N 0.000 description 1
- RCDOAYGHUCAQIH-KKFHFHRHSA-N CCOC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(C)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(C)c1)ccc1F)=O RCDOAYGHUCAQIH-KKFHFHRHSA-N 0.000 description 1
- ZIDQLVZJGPZLJL-MTCVILAZSA-N CCOC(C1=C(CN(CCO[C@@H]2C)[C@@H]2C(O)=O)NC(C2=N[C@@H](C3)C3S2)=NC1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCO[C@@H]2C)[C@@H]2C(O)=O)NC(C2=N[C@@H](C3)C3S2)=NC1c(c(Cl)c1)ccc1F)=O ZIDQLVZJGPZLJL-MTCVILAZSA-N 0.000 description 1
- GOEGDCHDZBAASO-UHFFFAOYSA-N CCOC(C1=C(CN2C(CO)COCC2)NC(c2ncc(OC)[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C(CO)COCC2)NC(c2ncc(OC)[s]2)=NC1c(c(Br)c1)ccc1F)=O GOEGDCHDZBAASO-UHFFFAOYSA-N 0.000 description 1
- OQXANPFPXJIJMQ-ZVSMTPAHSA-N CCOC(C1=C(CN2C(COC([C@H](C(C)C)N)=O)COCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C(COC([C@H](C(C)C)N)=O)COCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O OQXANPFPXJIJMQ-ZVSMTPAHSA-N 0.000 description 1
- IVWYKPVZTPJSPY-UJONTBEJSA-N CCOC(C1=C(CN2C[C@H](COC(C(C)(C)C)=O)OCC2)NC(C(/N=C\N)=N)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@H](COC(C(C)(C)C)=O)OCC2)NC(C(/N=C\N)=N)=NC1c(c(Br)c1)ccc1F)=O IVWYKPVZTPJSPY-UJONTBEJSA-N 0.000 description 1
- WDPCLLVOFLZNFF-CMQBZPNLSA-N CCOC(C1=C(CN2[C@H](CO)CCC2)NC(c2n[nH]cn2)=NC1C(C=CC(C1C)F)=C1Br)=O Chemical compound CCOC(C1=C(CN2[C@H](CO)CCC2)NC(c2n[nH]cn2)=NC1C(C=CC(C1C)F)=C1Br)=O WDPCLLVOFLZNFF-CMQBZPNLSA-N 0.000 description 1
- GCSVBOWHOWKBRE-UHFFFAOYSA-N CCOC(C1=C(CNCCOCC(C)C(O)=O)NC(c2nnc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CNCCOCC(C)C(O)=O)NC(c2nnc[s]2)=NC1c(c(Br)c1)ccc1F)=O GCSVBOWHOWKBRE-UHFFFAOYSA-N 0.000 description 1
- XWYVXQBWHUCSAH-PSUSGTTNSA-N CC[C@@H](C(COC[C@H]1N(CC(NC(c2ncc[s]2)=NC2c(c(Br)c3)ccc3F)=C2C(OCC)=O)CCOC1)=O)N Chemical compound CC[C@@H](C(COC[C@H]1N(CC(NC(c2ncc[s]2)=NC2c(c(Br)c3)ccc3F)=C2C(OCC)=O)CCOC1)=O)N XWYVXQBWHUCSAH-PSUSGTTNSA-N 0.000 description 1
- LXUVXPPWQFBOAF-UHFFFAOYSA-N CN(C)N(CCOC1)C1C(O)=O Chemical compound CN(C)N(CCOC1)C1C(O)=O LXUVXPPWQFBOAF-UHFFFAOYSA-N 0.000 description 1
- VWXDWBDQLMHVRX-UHFFFAOYSA-N CN1C(CC(O)=O)COCC1 Chemical compound CN1C(CC(O)=O)COCC1 VWXDWBDQLMHVRX-UHFFFAOYSA-N 0.000 description 1
- LJIYTRWQOOXPCZ-UHFFFAOYSA-N CN1CC(C(O)=O)OCC1 Chemical compound CN1CC(C(O)=O)OCC1 LJIYTRWQOOXPCZ-UHFFFAOYSA-N 0.000 description 1
- UASIDVJACYZUNC-UHFFFAOYSA-N Cc(nc[s]1)c1Cl Chemical compound Cc(nc[s]1)c1Cl UASIDVJACYZUNC-UHFFFAOYSA-N 0.000 description 1
- QLXOJLUHWBDVKZ-UHFFFAOYSA-O Cc1[nH+]cn[s]1 Chemical compound Cc1[nH+]cn[s]1 QLXOJLUHWBDVKZ-UHFFFAOYSA-O 0.000 description 1
- QMHIMXFNBOYPND-UHFFFAOYSA-N Cc1c[s]cn1 Chemical compound Cc1c[s]cn1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N Cc1n[nH]cn1 Chemical compound Cc1n[nH]cn1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
- LVVZGMYOXJQBLB-UHFFFAOYSA-N Cc1nc(F)c[s]1 Chemical compound Cc1nc(F)c[s]1 LVVZGMYOXJQBLB-UHFFFAOYSA-N 0.000 description 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N Cc1ncc[o]1 Chemical compound Cc1ncc[o]1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
- RQSCFNPNNLWQBJ-UHFFFAOYSA-N Cc1nnc[s]1 Chemical compound Cc1nnc[s]1 RQSCFNPNNLWQBJ-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N Ic1ccccn1 Chemical compound Ic1ccccn1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510324031.7A CN104926808B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210303033 | 2012-08-24 | ||
| CN2012103030334 | 2012-08-24 | ||
| CN2013101169493 | 2013-04-03 | ||
| CN201310116949 | 2013-04-03 | ||
| CN201510324031.7A CN104926808B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN201310373003.5A CN103626752B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310373003.5A Division CN103626752B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104926808A CN104926808A (zh) | 2015-09-23 |
| CN104926808B true CN104926808B (zh) | 2018-09-14 |
Family
ID=50149385
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510324031.7A Active CN104926808B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN201310373003.5A Active CN103626752B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310373003.5A Active CN103626752B (zh) | 2012-08-24 | 2013-08-23 | 二氢嘧啶类化合物及其在药物中的应用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9340538B2 (enExample) |
| EP (1) | EP2888241B1 (enExample) |
| JP (1) | JP6263533B2 (enExample) |
| KR (1) | KR102148678B1 (enExample) |
| CN (2) | CN104926808B (enExample) |
| AU (1) | AU2013305390C1 (enExample) |
| BR (1) | BR112015002858A2 (enExample) |
| CA (1) | CA2876690C (enExample) |
| DK (1) | DK2888241T3 (enExample) |
| ES (1) | ES2640049T3 (enExample) |
| HU (1) | HUE034919T2 (enExample) |
| MX (1) | MX2015002511A (enExample) |
| MY (1) | MY182403A (enExample) |
| PL (1) | PL2888241T3 (enExample) |
| PT (1) | PT2888241T (enExample) |
| RU (1) | RU2655914C9 (enExample) |
| SG (1) | SG11201408791TA (enExample) |
| TW (1) | TWI668217B (enExample) |
| WO (1) | WO2014029193A1 (enExample) |
| ZA (1) | ZA201500451B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| KR20150054795A (ko) * | 2012-09-10 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘 |
| CN103664899B (zh) * | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN104650069B (zh) * | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| RU2678990C1 (ru) * | 2013-11-19 | 2019-02-05 | Саншайн Лейк Фарма Ко., Лтд. | Соединения дигидропиримидина и их применение в фармацевтических препаратах |
| AU2014356986B2 (en) | 2013-11-27 | 2018-01-04 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| EP3114128B1 (en) | 2014-03-07 | 2019-01-02 | F. Hoffmann-La Roche AG | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| WO2015144093A1 (en) * | 2014-03-28 | 2015-10-01 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| CN105153164B (zh) * | 2014-05-30 | 2018-10-30 | 齐鲁制药有限公司 | 作为hbv抑制剂的二氢嘧啶并环衍生物 |
| WO2015180631A1 (zh) * | 2014-05-30 | 2015-12-03 | 南京明德新药研发股份有限公司 | 作为hbv抑制剂的二氢嘧啶并环衍生物 |
| WO2016012470A1 (en) * | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
| CN105859708B (zh) * | 2015-02-07 | 2020-01-21 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物的盐及其在药物中的应用 |
| ES2798598T3 (es) | 2015-03-16 | 2020-12-11 | Hoffmann La Roche | Tratamiento combinado con un agonista de TLR7 y un inhibidor de ensamblaje de la cápside del VHB |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| AU2016349685A1 (en) * | 2015-11-03 | 2018-03-15 | F. Hoffmann-La Roche Ag | Combination therapy of an HBV capsid assembly inhibitor and an interferon |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| AR107633A1 (es) | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
| MX384836B (es) | 2016-03-07 | 2025-03-14 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| WO2017198201A1 (en) * | 2016-05-19 | 2017-11-23 | Sunshine Lake Pharma Co., Ltd. | Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine |
| KR20190027814A (ko) | 2016-06-10 | 2019-03-15 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| JP2019526562A (ja) * | 2016-08-24 | 2019-09-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法 |
| CN107793409B (zh) * | 2016-09-05 | 2022-09-27 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| WO2018045911A1 (zh) * | 2016-09-09 | 2018-03-15 | 浙江海正药业股份有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| EP3508483B1 (en) * | 2016-11-18 | 2021-10-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| EP3645516A4 (en) * | 2017-06-27 | 2021-07-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS |
| US11247998B2 (en) | 2017-07-27 | 2022-02-15 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| NZ762994A (en) | 2017-08-28 | 2025-11-28 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| US11807623B2 (en) * | 2017-11-30 | 2023-11-07 | Arrakis Therapeutics, Inc. | Nucleic acid-binding photoprobes and uses thereof |
| WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CA3097784A1 (en) * | 2018-05-08 | 2019-11-14 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
| KR20210025596A (ko) * | 2018-06-26 | 2021-03-09 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 디하이드로피리미딘 유도체 및 hbv 감염 또는 hbv 유발성 질환의 치료에 있어서 이들의 용도 |
| CN108947996B (zh) * | 2018-07-12 | 2022-01-18 | 山东大学 | 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| AR116474A1 (es) | 2018-09-21 | 2021-05-12 | Enanta Pharm Inc | DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| CN109251201B (zh) * | 2018-11-03 | 2020-06-02 | 深圳市第二人民医院 | 一种抗hbv的含氮杂环化合物 |
| CN109232555B (zh) * | 2018-11-03 | 2020-06-02 | 深圳市第二人民医院 | 一种抗hbv的含氧杂环化合物 |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| WO2020193459A1 (en) | 2019-03-25 | 2020-10-01 | F. Hoffmann-La Roche Ag | Solid forms of a compound of hbv core protein allosteric modifier |
| SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US20220249647A1 (en) * | 2019-06-18 | 2022-08-11 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CN110204539B (zh) * | 2019-07-03 | 2021-07-23 | 山东大学 | 一种二氢嘧啶类前药及其制备方法和应用 |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021018237A1 (en) * | 2019-07-31 | 2021-02-04 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| KR20220119666A (ko) * | 2019-12-20 | 2022-08-30 | 얀센 파마슈티카 엔.브이. | 헤테로아릴디하이드로피리미딘 유도체 및 b형 간염 감염의 치료 방법 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| WO2022052923A1 (zh) * | 2020-09-08 | 2022-03-17 | 和博医药有限公司 | 二氢嘧啶类化合物、其应用 |
| AR124719A1 (es) | 2021-01-29 | 2023-04-26 | Janssen Sciences Ireland Unlimited Co | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| JP2024505709A (ja) * | 2021-02-05 | 2024-02-07 | ヘパジーン セラピューティクス（エイチケー）リミティド | フェニルジヒドロピリミジン系化合物及びその使用 |
| WO2022257942A1 (en) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
| CN116284080A (zh) * | 2023-02-23 | 2023-06-23 | 山东大学 | 一种含硼酸及硼酸频哪醇酯基团的二氢嘧啶类衍生物及其制备方法与应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305471A (zh) * | 1998-04-18 | 2001-07-25 | 拜尔公司 | 二氢嘧啶类化合物 |
| CN1134434C (zh) * | 1998-04-18 | 2004-01-14 | 拜尔公司 | 新型2-杂环取代的二氢嘧啶 |
| CN101104617A (zh) * | 2006-07-10 | 2008-01-16 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328169A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN101328168A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN101328170A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| CN101328171A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| CN101575318A (zh) * | 2009-06-25 | 2009-11-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| CN104603125A (zh) * | 2012-09-10 | 2015-05-06 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| CA2154633A1 (en) * | 1995-01-25 | 1996-07-26 | Paul Harry Sandstrom | Silica reinforced rubber composition and use in tires |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
| DOP2006000210A (es) * | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| WO2008024692A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | N-oxide aryl sulfones and sulfoxides |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| US9968650B2 (en) * | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| WO2013019967A1 (en) * | 2011-08-02 | 2013-02-07 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| EA026977B1 (ru) | 2012-01-06 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
-
2013
- 2013-08-23 RU RU2015110082A patent/RU2655914C9/ru active
- 2013-08-23 EP EP13830553.7A patent/EP2888241B1/en active Active
- 2013-08-23 PT PT138305537T patent/PT2888241T/pt unknown
- 2013-08-23 US US14/416,061 patent/US9340538B2/en active Active
- 2013-08-23 MY MYPI2015700218A patent/MY182403A/en unknown
- 2013-08-23 DK DK13830553.7T patent/DK2888241T3/en active
- 2013-08-23 WO PCT/CN2013/001001 patent/WO2014029193A1/en not_active Ceased
- 2013-08-23 CA CA2876690A patent/CA2876690C/en active Active
- 2013-08-23 AU AU2013305390A patent/AU2013305390C1/en active Active
- 2013-08-23 CN CN201510324031.7A patent/CN104926808B/zh active Active
- 2013-08-23 TW TW102130355A patent/TWI668217B/zh active
- 2013-08-23 ES ES13830553.7T patent/ES2640049T3/es active Active
- 2013-08-23 MX MX2015002511A patent/MX2015002511A/es unknown
- 2013-08-23 CN CN201310373003.5A patent/CN103626752B/zh active Active
- 2013-08-23 KR KR1020147036508A patent/KR102148678B1/ko active Active
- 2013-08-23 JP JP2015527761A patent/JP6263533B2/ja active Active
- 2013-08-23 PL PL13830553T patent/PL2888241T3/pl unknown
- 2013-08-23 HU HUE13830553A patent/HUE034919T2/en unknown
- 2013-08-23 BR BR112015002858A patent/BR112015002858A2/pt active Search and Examination
- 2013-08-23 SG SG11201408791TA patent/SG11201408791TA/en unknown
-
2015
- 2015-01-22 ZA ZA2015/00451A patent/ZA201500451B/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305471A (zh) * | 1998-04-18 | 2001-07-25 | 拜尔公司 | 二氢嘧啶类化合物 |
| CN1134434C (zh) * | 1998-04-18 | 2004-01-14 | 拜尔公司 | 新型2-杂环取代的二氢嘧啶 |
| CN101104617A (zh) * | 2006-07-10 | 2008-01-16 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328169A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN101328168A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN101328170A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| CN101328171A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| CN101575318A (zh) * | 2009-06-25 | 2009-11-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| CN104603125A (zh) * | 2012-09-10 | 2015-05-06 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104926808B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664925B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664897B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN109678859B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650068B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664899B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104945395B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN109111451B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN101903356A (zh) | 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用 | |
| CN104650070B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN110964023B (zh) | 稠合四环类化合物及其在药物中的应用 | |
| CN107793409B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN110862390A (zh) | 稠合三环类化合物及其在药物中的应用 | |
| HK40002930A (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| HK40002930B (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines Effective date of registration: 20200514 Granted publication date: 20180914 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20180914 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan) Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |